|
Synonyms: BMS-936564 | MDX-1338
Compound class:
Antibody
Comment: Ulocuplumab is an IgG4 kappa anti-CXCR4 monoclonal, being developed by Bristol-Myers Squibb as a potential oncolgy therapeutic.
Peptide sequences and structural details for this antibody are available from its IMGT/mAb-DB record. BLAST sequence analysis of the heavy and light chain peptide sequences of ulocuplumab, reveal identical matches with sequences claimed in patent US8450464 [5]. This identifies clone F7GL as the likely candidate for ulocuplumab. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Immunopharmacology Comments |
| Ulocuplumab is included in GtoImmuPdb as a novel immuno-oncology agent. It acts as a CXCR4 functional antagonist which blocks aberrant CXCR4-SDF-1 signalling in cancer cells. |
